Search results
Showing 631 to 645 of 2183 results for guidelines
This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.
This quality standard covers assessing, diagnosing and managing bronchiolitis in children. It describes high-quality care in priority areas for improvement.
This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
Subscribe to our GP reference panel and contribute to the development of NICE guidance in a quick and easy way.
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
COVID-19 rapid guideline: acute kidney injury in hospital (NG175)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
Renal and ureteric stones: assessment and management (NG118)
This guideline covers assessing and managing renal and ureteric stones. It aims to improve the detection, clearance and prevention of stones, so reducing pain and anxiety, and improving quality of life.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
How you can use our recommendations, tools and resources: cardiovascular disease
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
This quality standard covers increasing vaccine uptake among children and young people aged under 19 in groups and settings that have low immunisation coverage. It describes high-quality care in priority areas for improvement.
View quality statements for QS145Show all sections
Sections for QS145
- Quality statements
- Quality statement 1: Follow-up invitations
- Quality statement 2: Offering outstanding vaccinations
- Quality statement 3: Recording vaccinations
- Quality statement 4: Checking immunisation status at specific educational stages
- Quality statement 5: Checking immunisation status of young offenders and offering outstanding vaccinations
- Update information
- About this quality standard
Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.
We provide an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care.